-
公开(公告)号:US20190274554A1
公开(公告)日:2019-09-12
申请号:US16463136
申请日:2017-11-16
发明人: Chang No YOON , Hong Seog SEO , Won Seok HAN , Jin Kak LEE , Jun Seok LEE
摘要: Provided is a method of determining circulatory disease potential. The method includes: a user data receiving operation of receiving user data about a blood pressure and a blood flow of a user; a pattern calculating operation of calculating a three-dimensional (3D) user pattern for the user based on the received user data; a pattern comparing operation of comparing a comparison target pattern calculated based on data about blood pressures and blood flows of a normal person and a circulatory patient stored in a database, with the calculated user pattern; and a result output operation of outputting, based on a result of the comparison, circulatory disease potential visualizing to which of the normal person and the circulatory patient stored in the database the user is closer.
-
公开(公告)号:US20210393722A1
公开(公告)日:2021-12-23
申请号:US17288632
申请日:2019-10-31
发明人: Hong Seog SEO , Yong Jik LEE , Hyoung Ja KIM , Chang Bae JIN
IPC分类号: A61K36/28 , A61K31/216 , A23L33/10
摘要: The present invention relates to a composition for improving skin barrier damage and/or alleviating skin inflammation, wherein 3,5-dicaffeoylquinic acid isolated from an Aster glehni (AG) extract is introduced as an active ingredient of a cosmetic composition or a pharmaceutical composition for improving skim barrier damage and alleviating skin inflammation, thereby being effective in preventing and improving atopic dermatitis.
-
3.
公开(公告)号:US20160305931A1
公开(公告)日:2016-10-20
申请号:US14795163
申请日:2015-07-09
发明人: Byung Hwa JUNG , Jong Min CHOI , Hong Seog SEO
IPC分类号: G01N33/49
CPC分类号: G01N33/492 , G01N33/6893 , G01N2405/02 , G01N2405/04 , G01N2405/08 , G01N2570/00 , G01N2800/324
摘要: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.
摘要翻译: 本公开提供了使用一种或多种选自色氨酸,高丝氨酸,脂肪酸(16:1),脂肪酸(18:0),脂肪酸(18:1),脂肪酸 (18:2),脂肪酸(22:6),磷脂酰胆碱(PC)(34:2),PC(34:3),溶血磷脂酰胆碱(溶血卵磷脂)(16:0),溶血卵磷脂(18:0) 20:3),lysoPC(20:4),溶血卵磷脂(22:6),单甘油酯(18:1:0:0/0:0)和鞘磷脂(d18:2/16:0) 通过体内水平分析简单准确地诊断急性冠状动脉综合征以及发病前的症状。
-
公开(公告)号:US20180156774A1
公开(公告)日:2018-06-07
申请号:US15601262
申请日:2017-05-22
发明人: Byung Hwa JUNG , Jong Min CHOI , Hong Seog SEO
IPC分类号: G01N33/49
CPC分类号: G01N33/492 , G01N2800/324 , G01N2800/50 , G01N2800/60
摘要: The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.
-
-
-